Terms: = Lymphoma AND FH, HLRCC, 2271, ENSG00000091483, MCUL1, MCL, LRCC, P07954 AND Clinical Outcome
72 results:
1. SOX11/PRDX2 axis modulates redox homeostasis and chemoresistance in aggressive mantle cell lymphoma.
De Bolòs A; Sureda-Gómez M; Carreras-Caballé M; Rodríguez ML; Clot G; Beà S; Giné E; Campo E; Balsas P; Amador V
Sci Rep; 2024 Apr; 14(1):7863. PubMed ID: 38570586
[TBL] [Abstract] [Full Text] [Related]
2. B-cell receptor signaling activity identifies patients with mantle cell lymphoma at higher risk of progression.
Gambino S; Quaglia FM; Galasso M; Cavallini C; Chignola R; Lovato O; Giacobazzi L; Caligola S; Adamo A; Putta S; Aparo A; Ferrarini I; Ugel S; Giugno R; Donadelli M; Dando I; Krampera M; Visco C; Scupoli MT
Sci Rep; 2024 Mar; 14(1):6595. PubMed ID: 38503806
[TBL] [Abstract] [Full Text] [Related]
3. MYC protein is a high-risk factor in mantle cell lymphoma and identifies cases beyond morphology, proliferation and
Rodrigues JM; Hollander P; Schmidt L; Gkika E; Razmara M; Kumar D; Geisler C; Grønbæk K; Eskelund CW; Räty R; Kolstad A; Sundström C; Glimelius I; Porwit A; Jerkeman M; Ek S
Haematologica; 2024 Apr; 109(4):1171-1183. PubMed ID: 37646663
[TBL] [Abstract] [Full Text] [Related]
4. clinical outcome of Mantle Cell lymphoma patients with high-risk disease (high-risk MIPI-c or high p53 expression).
Scheubeck G; Jiang L; Hermine O; Kluin-Nelemans HC; Schmidt C; Unterhalt M; Rosenwald A; Klapper W; Evangelista A; Ladetto M; Jerkeman M; Ferrero S; Dreyling M; Hoster E
Leukemia; 2023 Sep; 37(9):1887-1894. PubMed ID: 37495776
[TBL] [Abstract] [Full Text] [Related]
5. Blastoid and Pleomorphic Mantle Cell lymphoma Demonstrate Distinct Clinicopathologic and Genetic Features.
Khanlari M; Mo H; Kim DH; Sakhdari A; Young KH; Jain P; Wang M; Li S; Kanagal-Shamanna R; Miranda RN; Vega F; Medeiros LJ; Ok CY
Am J Surg Pathol; 2023 Aug; 47(8):849-858. PubMed ID: 37288826
[TBL] [Abstract] [Full Text] [Related]
6. Bendamustine Plus Rituximab for Mantle Cell lymphoma: A Korean, Multicenter Retrospective Analysis.
Yi JH; Kim SJ; Lee JO; Lee GW; Kwak JY; Eom HS; Jo JC; Choi YS; Oh SY; Kim WS
Anticancer Res; 2022 Dec; 42(12):6083-6089. PubMed ID: 36456154
[TBL] [Abstract] [Full Text] [Related]
7. Bcl-2 Family Members Bcl-xL and Bax Cooperatively Contribute to Bortezomib Resistance in Mantle Cell lymphoma.
Luanpitpong S; Janan M; Yosudjai J; Poohadsuan J; Chanvorachote P; Issaragrisil S
Int J Mol Sci; 2022 Nov; 23(22):. PubMed ID: 36430955
[TBL] [Abstract] [Full Text] [Related]
8. The antibody drug conjugate VLS-101 targeting ROR1 is effective in CAR T-resistant mantle cell lymphoma.
Jiang VC; Liu Y; Jordan A; McIntosh J; Li Y; Che Y; Jessen KA; Lannutti BJ; Wang M
J Hematol Oncol; 2021 Aug; 14(1):132. PubMed ID: 34454548
[TBL] [Abstract] [Full Text] [Related]
9. SOX11, CD70, and Treg cells configure the tumor-immune microenvironment of aggressive mantle cell lymphoma.
Balsas P; Veloza L; Clot G; Sureda-Gómez M; Rodríguez ML; Masaoutis C; Frigola G; Navarro A; Beà S; Nadeu F; Giné E; López-Guillermo A; Martínez A; Ribera-Cortada I; Engel P; Quintanilla-Martínez L; Klapper W; Campo E; Amador V
Blood; 2021 Dec; 138(22):2202-2215. PubMed ID: 34189576
[TBL] [Abstract] [Full Text] [Related]
10. Targeted locus amplification to detect molecular markers in mantle cell and follicular lymphoma.
Genuardi E; Klous P; Mantoan B; Drandi D; Ferrante M; Cavallo F; Alessandria B; Dogliotti I; Grimaldi D; Ragaini S; Clerico M; Lo Schirico M; Saraci E; Yilmaz M; Zaccaria GM; Cortelazzo S; Vitolo U; Luminari S; Federico M; Boccadoro M; van Min M; Splinter E; Ladetto M; Ferrero S
Hematol Oncol; 2021 Aug; 39(3):293-303. PubMed ID: 33742718
[TBL] [Abstract] [Full Text] [Related]
11. Aggressive B-cell lymphoma with MYC/TP53 Dual Alterations Displays Distinct Clinicopathobiological Features and Response to Novel Targeted Agents.
Deng M; Xu-Monette ZY; Pham LV; Wang X; Tzankov A; Fang X; Zhu F; Visco C; Bhagat G; Dybkaer K; Chiu A; Tam W; Zu Y; Hsi ED; You H; Huh J; Ponzoni M; Ferreri AJM; Møller MB; Parsons BM; Hagemeister F; van Krieken JH; Piris MA; Winter JN; Li Y; Xu B; Liu P; Young KH
Mol Cancer Res; 2021 Feb; 19(2):249-260. PubMed ID: 33154093
[TBL] [Abstract] [Full Text] [Related]
12. A Cyclin D1-Dependent Transcriptional Program Predicts clinical outcome in Mantle Cell lymphoma.
Demajo S; Albero R; Clot G; Castellano G; Navarro A; Capdevila C; Enjuanes A; Nadeu F; Giné E; Pinyol M; Jaffe ES; Ott G; Staudt LM; Rosenwald A; Scott DW; Rimsza LM; López-Guillermo A; Beà S; Campo E; Jares P
Clin Cancer Res; 2021 Jan; 27(1):213-225. PubMed ID: 33046520
[TBL] [Abstract] [Full Text] [Related]
13. TIGIT Expression Is Associated with T-cell Suppression and Exhaustion and Predicts clinical outcome and Anti-PD-1 Response in Follicular lymphoma.
Yang ZZ; Kim HJ; Wu H; Jalali S; Tang X; Krull JE; Ding W; Novak AJ; Ansell SM
Clin Cancer Res; 2020 Oct; 26(19):5217-5231. PubMed ID: 32631956
[TBL] [Abstract] [Full Text] [Related]
14. Maternal embryonic leucine zipper kinase is a novel target for diffuse large B cell lymphoma and mantle cell lymphoma.
Maes A; Maes K; Vlummens P; De Raeve H; Devin J; Szablewski V; De Veirman K; Menu E; Moreaux J; Vanderkerken K; De Bruyne E
Blood Cancer J; 2019 Nov; 9(12):87. PubMed ID: 31740676
[TBL] [Abstract] [Full Text] [Related]
15. DNA Damage Response Inhibitor Combinations Exert Synergistic Antitumor Activity in Aggressive B-Cell lymphomas.
Restelli V; Lupi M; Chilà R; Vagni M; Tarantelli C; Spriano F; Gaudio E; Bertoni F; Damia G; Carrassa L
Mol Cancer Ther; 2019 Jul; 18(7):1255-1264. PubMed ID: 31064869
[TBL] [Abstract] [Full Text] [Related]
16. Expression of GNAZ, encoding the Gα
Mundt F; Merrien M; Nygren L; Sutton LA; Christensson B; Wahlin BE; Rosenquist R; Sander B; Wasik AM
Br J Haematol; 2019 May; 185(4):708-712. PubMed ID: 30788840
[TBL] [Abstract] [Full Text] [Related]
17. Lenalidomide for the treatment of mantle cell lymphoma.
Morabito F; Skafi M; Recchia AG; Kashkeesh A; Hindiyeh M; Sabatleen A; Morabito L; Alijanazreh H; Hamamreh Y; Gentile M
Expert Opin Pharmacother; 2019 Apr; 20(5):487-494. PubMed ID: 30608891
[TBL] [Abstract] [Full Text] [Related]
18. Development of venetoclax for therapy of lymphoid malignancies.
Zhu H; Almasan A
Drug Des Devel Ther; 2017; 11():685-694. PubMed ID: 28331288
[TBL] [Abstract] [Full Text] [Related]
19. LncRNA MALAT1 promotes development of mantle cell lymphoma by associating with EZH2.
Wang X; Sehgal L; Jain N; Khashab T; Mathur R; Samaniego F
J Transl Med; 2016 Dec; 14(1):346. PubMed ID: 27998273
[TBL] [Abstract] [Full Text] [Related]
20. Minimal residual disease in mantle cell lymphoma: insights into biology and impact on treatment.
Hoster E; Pott C
Hematology Am Soc Hematol Educ Program; 2016 Dec; 2016(1):437-445. PubMed ID: 27913513
[TBL] [Abstract] [Full Text] [Related]
[Next]
